Resumo

BUSTOS SANCHEZ, Jose Luis  e  AYALA GARCIA, Martín Germán. Fingolimod for multiple sclerosis. Acta Neurol Colomb. [online]. 2013, vol.29, n.4, pp.266-273. ISSN 0120-8748.

Fingolimod was the first oral therapy for Multiple Sclerosis approved worldwide as a disease-modifying treatment for the relapsing-remitting form. It Is an immunosuppressant prodrug, homologue with sphingosine. The approval for its application has scientific support in two collaborative clinical trials: TRANSFORMS and FREEDOMS. Serious side effects reported during these studies (in more than two patients) were basal cell carcinoma, bradycardia within the first six hours of administration and lower respiratory tract infection. Two patients died: one of them with herpetic encephalitis and the other one of a varicella zoster infection. There is 0.3% risk of developing macular edema.

Palavras-chave : Demyelinating; Autoinmune Disease; Inmunosuppression; Multiple Sclerosis; Recurrense (MeSH).

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )